{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:58:13Z","timestamp":1793059093379,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"vor","delay-in-days":2637,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1093\/annonc\/mdr626","type":"journal-article","created":{"date-parts":[[2012,2,22]],"date-time":"2012-02-22T07:36:25Z","timestamp":1329896185000},"page":"2409-2414","source":"Crossref","is-referenced-by-count":63,"title":["Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors"],"prefix":"10.1016","volume":"23","author":[{"given":"L.","family":"Schirosi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Nannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Nicoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cavazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Valli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Buti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Garagnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Sartori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Buttitta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Felicioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Migaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Rea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Di Chiara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Mengoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdr626_bb0010","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.lungcan.2008.01.014","article-title":"A review of thymic tumours","volume":"60","author":"Srirajaskanthan","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1093\/annonc\/mdr626_bb0015","series-title":"Pathology and Genetics of Tumours of the Lung, Thymus and Heart","first-page":"93","article-title":"Tumours of the thymus. WHO Classification of Tumours","volume":"Vol. 10","author":"Marx","year":"2004"},{"key":"10.1093\/annonc\/mdr626_bb0020","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.thorsurg.2010.08.010","article-title":"Thymic carcinoma: is it a separate entity? From molecular to clinical evidence","volume":"21","author":"Marx","year":"2011","journal-title":"Thorac Surg Clin"},{"key":"10.1093\/annonc\/mdr626_bb0025","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/01.coc.0000227481.36109.e7","article-title":"Systemic treatment of malignant thymoma. A decade experience at a single institution","volume":"29","author":"Giaccone","year":"2006","journal-title":"Am J Clin Oncol"},{"key":"10.1093\/annonc\/mdr626_bb0030","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/path.1514","article-title":"KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas","volume":"202","author":"Pan","year":"2004","journal-title":"J Pathol"},{"key":"10.1093\/annonc\/mdr626_bb0035","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1378\/chest.128.1.140","article-title":"Immunohistochemical KIT (CD117) expression in thymic epithelial tumors","volume":"128","author":"Nakagawa","year":"2005","journal-title":"Chest"},{"key":"10.1093\/annonc\/mdr626_bb0040","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1056\/NEJM200406173502523","article-title":"Thymic carcinoma with overexpression of mutated KIT and the response to imatinib","volume":"350","author":"Strobel","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdr626_bb0045","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.lungcan.2008.03.013","article-title":"Mutational status of EGFR and KIT in thymoma and thymic carcinoma","volume":"62","author":"Yoh","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1093\/annonc\/mdr626_bb0050","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.lungcan.2008.03.035","article-title":"Absence of gene mutations in KIT-positive thymic epithelial tumors","volume":"62","author":"Tsuchida","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1093\/annonc\/mdr626_bb0055","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/JTO.0b013e3181a52e25","article-title":"Long lasting response to the multikinase inhibitor bay 43-9006 (sorafenib) in a heavily pretreated metastatic thymic carcinoma","volume":"4","author":"Bisagni","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1093\/annonc\/mdr626_bb0060","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1158\/1078-0432.CCR-09-0644","article-title":"Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas","volume":"15","author":"Girard","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdr626_bb0065","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1097\/JTO.0b013e3181e96e30","article-title":"Expression and mutational status of c-kit in thymic epithelial tumors","volume":"5","author":"Petrini","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1093\/annonc\/mdr626_bb0070","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.lungcan.2010.09.011","article-title":"Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation","volume":"71","author":"Disel","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1093\/annonc\/mdr626_bb0075","doi-asserted-by":"crossref","first-page":"e803","DOI":"10.1200\/JCO.2011.36.6427","article-title":"Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma","volume":"29","author":"Buti","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr626_bb0080","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.hoc.2008.03.007","article-title":"Molecular pathology of thymic epithelial neoplasms","volume":"22","author":"Kuhn","year":"2008","journal-title":"Hematol Oncol Clin North Am"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mdr626_bb0085","doi-asserted-by":"crossref","first-page":"S291","DOI":"10.1097\/JTO.0b013e3181f209b9","article-title":"Thymic tumors. Relevant molecular data in the clinic","volume":"5","author":"Girard","year":"2010","journal-title":"J Thorac Oncol"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mdr626_bb0090","doi-asserted-by":"crossref","first-page":"S361","DOI":"10.1097\/JTO.0b013e3181f21114","article-title":"Targeted therapy for advanced thymic tumors","volume":"5","author":"Rajan","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1093\/annonc\/mdr626_bb0095","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/path.2798","article-title":"The GIST paradigm: lessons for other kinase-driven cancers","volume":"223","author":"Antonescu","year":"2011","journal-title":"J Pathol"},{"key":"10.1093\/annonc\/mdr626_bb0100","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s12032-008-9100-0","article-title":"Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report","volume":"26","author":"Li","year":"2009","journal-title":"Med Oncol"},{"key":"10.1093\/annonc\/mdr626_bb0105","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1200\/JCO.2006.08.8963","article-title":"Dasatinib induces a response in malignant thymoma","volume":"24","author":"Chuah","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr626_bb0110","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1200\/JCO.2010.30.2455","article-title":"Good clinical response to imatinib mesylate in atypical thymic carcinoid with KIT overexpression","volume":"29","author":"Hamada","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr626_bb0115","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1097\/JTO.0b013e3181b6be57","article-title":"Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas","volume":"4","author":"Giaccone","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1093\/annonc\/mdr626_bb0120","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/sj.bjc.6605740","article-title":"Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience","volume":"103","author":"Strobel","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdr626_bb0125","series-title":"Imatinib mesylate in thymic epithelial malignancies. Cancer Chemother Pharmacol","author":"Palmieri","year":"2011"},{"key":"10.1093\/annonc\/mdr626_bb0130","first-page":"266","article-title":"Treatment monitoring with 18F-FDG PET in metastatic thymoma after 90Y-dotatoc and selective internal radiation treatment (SIRT)","volume":"12","author":"Vasamiliette","year":"2009","journal-title":"Hell J Nucl Med"},{"key":"10.1093\/annonc\/mdr626_bb0135","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.ejca.2006.01.030","article-title":"KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours","volume":"42","author":"Debiec-Rychter","year":"2006","journal-title":"Eur J Cancer"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419351968?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419351968?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/23\/9\/2409\/13787862\/mdr626.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T09:29:31Z","timestamp":1624440571000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419351968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0923753419351968"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdr626","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}